One Stop Shop for All Your Market Research Reports

Global DTaP and Tdap Vaccines Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

Pertussis vaccine is used for whooping cough. This vaccine is available only in combination with other vaccines. Pertussis vaccination is recommended for all children, babies, teens, and pregnant women. Diphtheria, tetanus, and pertussis (DTaP) vaccines are given to children younger than seven years old, while tetanus, diphtheria, and pertussis (Tdap) vaccines are given to older children and adults. Childhood vaccination is one of the safest and cost-effective ways for pertussis-free environment. The World Health Organization (WHO) and Centers for Disease Control and Prevention (CDC) recommend all children should be routinely vaccinated for pertussis. According to WHO in 2015, about 86% of infants received three doses of diphtheria-tetanus-pertussis (DTP3) vaccine worldwide to protect them against infectious diseases. In 2015, procurement of DTwP vaccine through UNICEF had reached 5.8 million doses for 18 countries and territories out of which four countries such as Egypt, Morocco, Uzbekistan, and Zimbabwe accounted for more than 80% of UNICEF?s total procurement. Factors such as high birth rate, increase in number of geriatric population, government initiatives, growth in adoption of pertussis vaccination, and government insurance and reimbursement scenario are projected to drive the pertussis vaccine market globally. According to WHO in 2015, 126 countries had reached at least 90% coverage of diphtheria-tetanus-pertussis vaccine. On the other hand, factors such as vaccine injuries and adverse event are expected to hinder the growth of the pertussis vaccine market globally. In the U.S. in 2015, there had been 7 claims filed in the federal Vaccine Injury Compensation Program (VICP) for injuries and deaths following pertussis vaccination, including three deaths and four serious injuries. The pertussis vaccine market has been segmented by product type, vaccine type, age group, end-user, and geography. In terms of product type, the pertussis vaccine market is classified into DTaP vaccine and Tdap vaccine. The DTaP vaccine segment includes products such as Daptacel, Infanrix, Kinrix, Pediarix, Pentacel, and Quaracel. The Tdap vaccine segment comprises products such as Boostrix and Adacel. In terms of vaccine type, the pertussis vaccine market is classified into whole-cell vaccine and acellular vaccine. The acellular vaccine segment is highly used owing to less side effect. The acellular vaccine is about 71%?85% effective, whereas whole-cell vaccine is about 78% effective. In terms of age group, the pertussis vaccine market is classified into adult and pediatric. In terms of end-user, the market is classified into hospitals, clinics, and vaccination centers. Geographically, the pertussis vaccine market is classified into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa. North America dominates the pertussis vaccine market due to growth in number of geriatric population and increase in pertussis death rate in the U.S, which drive the pertussis vaccine market. In 2014, according to the CDC, 28,660 cases of pertussis were reported in the U.S. The North America market is followed by the Europe and Asia Pacific markets. Asia Pacific is expected to grow at a higher rate due to rapid population growth, increase in adoption for vaccination, and growth in prevalence of infectious disease. These factors are expected to fuel the pertussis vaccine market. In the Asia Pacific region, Thailand accounts for 99% in pertussis vaccine coverage, followed by Japan and China with 98% and 97%, respectively. Developing countries such as Brazil, South Africa, and Mexico are estimated to create good opportunity for the pertussis vaccine market growth attributing to rise in number of government and private health care insurance coverage, increase in health care expenditure, and growth in awareness among people. Scope of the Report: This report focuses on the DTaP and Tdap Vaccines in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. The worldwide market for DTaP and Tdap Vaccines is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study. Market Segment by Manufacturers, this report covers Sanofi Pasteur GlaxoSmithKline Protein Sciences Corporation Novartis AG Seqirus Merck Sharp & Dohme Corp Astellas Pharma US, Inc Pfizer Inc Johnson & Johnson Lanzhou Institute of Biological Products Co., Ltd AstraZeneca Emergent BioSolutions Inc Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico) Europe (Germany, France, UK, Russia and Italy) Asia-Pacific (China, Japan, Korea, India and Southeast Asia) South America (Brazil, Argentina, Colombia etc.) Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Market Segment by Type, covers DTaP Td Tdap Market Segment by Applications, can be divided into Adult Pediatric There are 15 Chapters to deeply display the global DTaP and Tdap Vaccines market. Chapter 1, to describe DTaP and Tdap Vaccines Introduction, product scope, market overview, market opportunities, market risk, market driving force; Chapter 2, to analyze the top manufacturers of DTaP and Tdap Vaccines, with sales, revenue, and price of DTaP and Tdap Vaccines, in 2016 and 2017; Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017; Chapter 4, to show the global market by regions, with sales, revenue and market share of DTaP and Tdap Vaccines, for each region, from 2013 to 2018; Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions; Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018; Chapter 12, DTaP and Tdap Vaccines market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023; Chapter 13, 14 and 15, to describe DTaP and Tdap Vaccines sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
Table of Contents 1 Market Overview 1.1 DTaP and Tdap Vaccines Introduction 1.2 Market Analysis by Type 1.2.1 DTaP 1.2.2 Td 1.2.3 Tdap 1.3 Market Analysis by Applications 1.3.1 Adult 1.3.2 Pediatric 1.4 Market Analysis by Regions 1.4.1 North America (United States, Canada and Mexico) 1.4.1.1 United States Mar
Inquiry Before Buying

Request Sample

Share This Report

Our Clients

Payment Mode
Single User US $ 3480
Multi User US $5220
Corporate User US $6960
About this Report
Report ID 306795
Category
  • Pharmaceuticals and Healthcare
Published on 31-Aug
Number of Pages 137
Publisher Name Global Info Research
Editor Rating
★★★★★
★★★★★
(30)